Loading...
  • patients
  • To ascertain feasibility (safety) and efficacy of the use of intensive chemotherapy regimen (busulfan and cyclophosphamide) followed by allogeneic bone marrow transplantation in patients with leukemia, myelodysplastic syndromes, multiple myeloma, and lymphoma. (clinicaltrials.gov)
  • bone marrow
  • When the Johns Hopkins team tested the drug in a mouse model of leukemia, they found that it not only eliminated the presence of leukemic cells within 10 days of treatment but also that the mice lived an average of more than 100 days following treatment, to study completion, and resumed normal bone marrow activity. (medindia.net)
  • In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. (healthcanal.com)
  • FLT3
  • But when FLT3 is mutated in some AML patients, the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition likely to relapse after treatment. (medindia.net)
  • Small led a team of researchers who originally cloned the FLT3 gene and linked it to leukemia a decade ago. (medindia.net)
  • In a series of experiments with the drug, Small, postdoctoral fellow Hayley Ma, Ph.D., and others found that the amount of TTT-3002 needed to block FLT3 activity in human leukemia cell lines was six- to sevenfold lower than for the most potent inhibitor currently in clinical trials. (medindia.net)
  • For the clinical trial, researchers enrolled 137 AML patients, the majority of whom carried a mutation called FLT3-ITD in a gene within their leukemia cells. (healthcanal.com)
  • In about a quarter of patients with AML, the disease mutates FLT3 so that the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition harder to treat. (healthcanal.com)
  • Recognition
  • Discovered the first linkage between the major histocompatibility complex (MHC) and disease-mouse leukemia-opening the way for the recognition of the importance of the MHC in the immune response (1964). (wikipedia.org)
  • Journal
  • The study, led by Dr. Caius Radu, an associate professor of molecular and medical pharmacology at UCLA, and Dr. David Nathanson, an assistant professor of molecular and medical pharmacology, was published in the Journal of Experimental Medicine . (eurekalert.org)
  • The Journal of Experimental Medicine. (wikipedia.org)
  • Society
  • Old was also a member of the American Association for Cancer Research, New York Academy of Sciences, Reticuloendothelial Society, Society of Experimental Biology and Medicine, American Association for the Advancement of Science, American Association of Immunologists, National Academy of Sciences, the Academy of Cancer Immunology, and the American Academy of Arts and Sciences. (wikipedia.org)